Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Edward Li, PharmD, MPH
Advertisement
Articles by Edward Li, PharmD, MPH
Advertisement
Latest Updated Articles
Budget Impact Analysis of Biosimilar Natalizumab in the USPublished: May 17th 2024 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
2
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
3
New Partnership Model Boosts Maternal Outcomes in Medicaid ACOs
4
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
5
